Berna YILDIRIM, Ahmet Taner SÜMBÜL, Erkan TOPKAN, Yurday ÖZDEMİR, Ali Ayberk Besen, Ozan Cem GÜLER, Ali Murat SEDEF, Cem ÖNAL

Adjuvant uzatılmış temozolamid tedavisinin glioblastoma multiforme hastalarının sağkalımına etkisi

Amaç: Retrospektif bu çalışmanın amacı cerrahi/biyopsi ile glioblastoma multiforme tanısı almış, kemoradyoterapi uygulanmış hastalarda uzatılmış temozolamid kullanımının genel ve progresyonsuz sağkalım etkisini araştırmak olarak belirlendi.Gereç ve Yöntem: Kliniğimize başvuran cerrahi/biyopsi ile glioblastoma multiforme tanısı almış 225 hastadan, temozolamid ile birlikte radyoterapi tedavisi uygulandıktan sonra, ≤6 ay ve >6 ay süreyle adjuvan temozolamid kemoterapisi uygulanmış 116 hastatedavi toleransı, genel ve progresyonsuz sağkalımları arasındaki farklar retrospektif olarak incelendi.Bulgular: Hastaların ortalama takip süresi 18 ay (2-125 ay) olarak belirlenirken, 65(%56) hasta halen hayattadır. Uzatılmış temozolamid (>6 ay) olan grupta genel sağkalım daha uzun tespit edilirken istatistiksel bir fark tek değişkenli analizde tespit edilememiştir sırasıyla 49.0 (≤6)vs 68.33 ay(>6). Ancak progresyonsuz sağkalım süresi uzatılmış temozolamid grubunda standart temozolamid alan gruba göre istatistiksel olarak anlamlı oranda uzun saptanmıştır 14 (>6)vs 9 ay(≤6). Gruplar arasında anlamlı bir yan etki farklılığı görülmemiştir.Sonuç: Çalışmamızda glioblastoma multiforme tanısı almış hastalarda uzatılmış temozolamid kullanımı hastaların progresyonsuz sağkalım ve genel sağkalımlarının belirgin oranda artmasına neden olur.

Anahtar Kelimeler:

Glioblastoma Multiforme, Radyoterapi, Kemoterapi

Effect of adjuvant extended temozolamide treatment in survival of patients with glioblastoma multiforme

Purpose: The aim of this retrospective cohort study was to evaluate the prognostic effect extended temozolamide on survival outcomes of glioblastoma multiforme patients who were underwent surgery/biopsy followed treated with definitive chemo-radiotherapy.Materials and Methods: We retrospectively analyzed the datas of 225 patients with gliablastoma multiforme whom admitted to our clinic All patients were completed concomitant chemoradiotherapy with temozolamide and adjuvant temozolamide therapy at least for six months or more. Patients were divided into two groups as standart and extended temozolamid therapy group as using temozolamide therapy for at least 6 months or more. Results: The median follow-up of the whole patients18 (range 2-125) months, 65 patients (56%) were alive. Extended temozolamide (>6) was associated with longer survival, but was not significantly with survival outcomes in the univariate analysis (49.0 vs 68.33 months;p=0.082). However, progression free survival analysis demonstrated that the patient in extended temozolamide group had paramount extended progression free survival (14 vs 9 months) than other group in standart cycle temozolamide. Conclusion: Our study show that extended temozolamide is well tolerated and leads to a significantly increase in progression free survival and overall survival in newly diagnosed patients with glioblastoma multiforme.

Keywords:

Glioblastoma multiforme, radiotherapy, chemotherapy,

PDF

___

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
3. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose- dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31:4085-91.
4. Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol. 2012;108:173-77.
5. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127-33.
6. Bhandari M, Gandhi AK, Devnani B, Kumar P, Sharma DN, Julka PK. comparative study of adjuvant temozolomide six cycles versus extended 12 cycles in newly diagnosed glioblastoma multiforme. J Clin Diagn Res. 2017;11:XC04-8.
7. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-82.
8. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601-6.
9. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010;12:164–72
10. Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperrière N et al. Canadian recommendations for the treatment of glioblastoma multiforme.; Canadian GBM Recommendations Committee.Curr Oncol. 2007;14:110-7.
11. Refae AA, Ezzat A, Salem DA, Mahrous M. Protracted adjuvant temozolomide in glioblastoma multiforme. J Cancer Ther. 2015;6:748.
12. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007;68:688-90.
13. Barbagallo GMV, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G et al. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus. 2014;37(6):E4.
14. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F et al. Long- term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol. 2010;136:1691-5.